GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Labiana Health SA (XMAD:LAB) » Definitions » Asset Impairment Charge

Labiana Health (XMAD:LAB) Asset Impairment Charge : €0.00 Mil (TTM As of Dec. 2022)


View and export this data going back to 2022. Start your Free Trial

What is Labiana Health Asset Impairment Charge?

Labiana Health's Asset Impairment Charge for the six months ended in Dec. 2022 was €0.00 Mil. Its Asset Impairment Charge for the trailing twelve months (TTM) ended in Dec. 2022 was €0.00 Mil.


Labiana Health Asset Impairment Charge Historical Data

The historical data trend for Labiana Health's Asset Impairment Charge can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Labiana Health Asset Impairment Charge Chart

Labiana Health Annual Data
Trend Dec20 Dec21 Dec22
Asset Impairment Charge
- - -

Labiana Health Semi-Annual Data
Dec20 Dec21 Jun22 Dec22
Asset Impairment Charge - - - -

Labiana Health Asset Impairment Charge Calculation

Asset Impairment Charge is the charge against earnings resulting from the aggregate write down of all assets from their carrying value to their fair value.

Asset Impairment Charge for the trailing twelve months (TTM) ended in Dec. 2022 adds up the semi-annually data reported by the company within the most recent 12 months, which was €0.00 Mil.


Labiana Health Asset Impairment Charge Related Terms

Thank you for viewing the detailed overview of Labiana Health's Asset Impairment Charge provided by GuruFocus.com. Please click on the following links to see related term pages.


Labiana Health (XMAD:LAB) Business Description

Traded in Other Exchanges
N/A
Address
Avenida Europa, 34 1st D, Pozuelo de Alarcon, Madrid, ESP, 28023
Labiana Health SA is a manufacturer of pharmacological products for veterinary use. The company's activities include GMP manufacturer for EU animal and human health industries, manufacturer specialized in sterile and lyophilized dosage forms, source of development, acquisition, and licensing of molecules such as Fosfomycin Trometamol.